Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.4.3.13 (
lysyl oxidase
)
1,248
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lysyl oxidase is an extracellular enzyme critical for the normal biosynthesis of collagens and elastin. In addition,
lysyl oxidase
reverts ras-mediated transformation, and
lysyl oxidase
expression is down-regulated in human cancers. Since suramin inhibits growth factor signaling pathways and induces
lysyl oxidase
in ras-transformed NIH3T3 cells (RS485 cells), we sought to investigate the effects of suramin on the phenotype of transformed cells and the role of
lysyl oxidase
in mediating these effects.
Suramin
treatment resulted in a more normal phenotype as judged by growth rate, cell cycle parameters, and morphology. beta-aminopropionitrile, the selective inhibitor of
lysyl oxidase
enzyme activity, was remarkably unable to block suramin-induced reversion. By contrast, ectopic antisense
lysyl oxidase
demonstrated that
lysyl oxidase
gene expression mediated phenotypic reversion. Since
lysyl oxidase
is synthesized as a 50 kDa precursor and processed to a 30 kDa active enzyme and 18 kDa propeptide, the effects of these two products on the transformed phenotype of RS485 cells were then directly assessed in the absence of suramin. Here we report, for the first time, that the
lysyl oxidase
propeptide, and not the
lysyl oxidase
enzyme, inhibits ras-dependent transformation as determined by effects on cell proliferation assays, growth in soft agar, and Akt-dependent induction of NF-kappaB activity. Thus, the
lysyl oxidase
propeptide, which is released during extracellular proteolytic processing of pro-
lysyl oxidase
, functions to inhibit ras-dependent cell transformation.
...
PMID:The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. 1527 20